Article
World’s First Clinical Case of Gene-Activated Bone Substitute Application
1 Jan 2016
Abstract excerpt
Treatment of patients with large bone defects is a complex clinical problem. We have initiated the first clinical study of a gene-activated bone substitute composed of the collagen-hydroxyapatite scaffold and plasmid DNA encoding vascular endothelial growth factor. The first patient with two nonunions of previously reconstructed mandible was enrolled into the study. Scar tissues were excised; bone defects (5-14...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
